Filing Details

Accession Number:
0001209191-23-040024
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-28 16:01:12
Reporting Period:
2023-06-28
Accepted Time:
2023-06-28 16:01:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802768 Royalty Pharma Plc RPRX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1507678 G. Pablo Legorreta C/O Royalty Pharma Plc
110 E. 59Th Street
New York NY 10022
Ceo, Chairman Of The Board Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Ordinary Shares Acquisiton 2023-06-28 130,000 $29.51 600,000 No 4 P Indirect By Legorreta 2023 SR Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Legorreta 2023 SR Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Ordinary Shares 63,795 Direct
Class A Ordinary Shares 460,139 Indirect By Legorreta Investments LLC
Class A Ordinary Shares 1,284,590 Indirect By GST-Exempt Legorreta 2012 Family Trust
Class A Ordinary Shares 41,306 Indirect By GST-Exempt Legorreta 2020 Family Trust
Class A Ordinary Shares 10,000 Indirect By Child
Class A Ordinary Shares 10,000 Indirect By Child
Class A Ordinary Shares 123,310 Indirect By IRRA
Class A Ordinary Shares 118,500 Indirect By SEP/IRA
Class A Ordinary Shares 1,040,410 Indirect By Legorreta Children 2002 Trust
Class A Ordinary Shares 6,930 Indirect By Spouse
Footnotes
  1. Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program.
  2. The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $29.40 to $29.60. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.